Raptor Pharmaceutical Licenses Intellectual Property Related to Parkinson's Disease From Universite Laval

22-Jun-2012 - USA

Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's disease from Université Laval.

Raptor's agreement with Laval provides exclusive rights to technology related to the use of cysteamine and related compounds to potentially modify the progression of Parkinson's Disease. Researchers at Laval reported that administration of cystamine (an oxidized form of cysteamine) in an animal model of Parkinson's Disease showed signs of preventing neuron loss and rescuing neurons undergoing a degenerative process. Signs of restoration and partial reversal of behavioral impairments were also observed.

Dr. Patrice P. Rioux, Raptor's Chief Medical Officer, stated, "The agreement with Laval extends our existing portfolio in neurodegenerative diseases. We are currently conducting a Phase 2/3 clinical trial in France of Delayed-release Cysteamine Bitartrate capsules (RP103), for the potential treatment of Huntington's Disease. The researchers at Laval have compiled a solid preclinical foundation which, when combined with the existing safety profile of cysteamine, may enable us to more rapidly advance this program for the potential treatment of Parkinson's Disease in to a Phase 2 clinical trial. We plan to seek grant support to help fund the clinical development of RP103 in Parkinson's, as we have done with our Huntington's and NASH programs."

https://www.bionity.com/en/news/138470/raptor-pharmaceutical-licenses-intellectual-property-related-to-parkinson-s-disease-from-universite-laval.html